{"id":"sofosbuvir-velpatasvir-oral-tablet-epclusa","safety":{"commonSideEffects":[{"rate":"14-18%","effect":"Headache"},{"rate":"11-14%","effect":"Fatigue"},{"rate":"7-10%","effect":"Diarrhea"},{"rate":"5-8%","effect":"Nausea"},{"rate":"4-6%","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog that inhibits the HCV NS5B RNA-dependent RNA polymerase, preventing viral RNA synthesis. Velpatasvir is an NS5A inhibitor that blocks a multifunctional viral protein essential for HCV replication and virion assembly. Together, this combination directly targets two critical steps in the HCV life cycle, achieving high cure rates across multiple HCV genotypes.","oneSentence":"Sofosbuvir and velpatasvir work together to inhibit hepatitis C virus (HCV) replication by blocking the NS5B polymerase and NS5A protein, respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:43.845Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, all genotypes (1-6), with or without cirrhosis"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epclusa"],"phase":"marketed","status":"active","brandName":"Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]","genericName":"Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]","companyName":"Ohio State University","companyId":"ohio-state-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir and velpatasvir work together to inhibit hepatitis C virus (HCV) replication by blocking the NS5B polymerase and NS5A protein, respectively. Used for Chronic hepatitis C virus (HCV) infection, all genotypes (1-6), with or without cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}